Altered expression of Sialyl Lewis X in experimental models of Parkinson’s disease
Open Access
- 10 January 2024
- journal article
- research article
- Published by Springer Nature in Journal of Molecular Medicine
- Vol. 102 (3) , 365-377
Abstract
The mechanisms underlying neurodegeneration in Parkinson’s disease (PD) are still not fully understood. Glycosylation is an important post-translational modification that affects protein function, cell-cell contacts and inflammation and can be modified in pathologic conditions. Although the involvement of aberrant glycosylation has been proposed for PD, the knowledge of the diversity of glycans and their role in PD is still minimal. Sialyl Lewis X (sLeX) is a sialylated and fucosylated tetrasaccharide with essential roles in cell-to-cell recognition processes. Pathological conditions and pro-inflammatory mediators can up-regulate sLeX expression on cell surfaces, which has important consequences in intracellular signalling and immune function. Here, we investigated the expression of this glycan using in vivo and in vitro models of PD. We show the activation of deleterious glycation-related pathways in mouse striatum upon treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), a toxin-based model of PD. Importantly, our results show that MPTP triggers the presentation of more proteins decorated with sLeX in mouse cortex and striatum in a time-dependent manner, as well as increased mRNA expression of its rate-limiting enzyme fucosyltransferase 7. sLeX is expressed in neurons, including dopaminergic neurons, and microglia. Although the underlying mechanism that drives increased sLeX epitopes, the nature of the protein scaffolds and their functional importance in PD remain unknown, our data suggest for the first time that sLeX in the brain may have a role in neuronal signalling and immunomodulation in pathological conditions. Key messages: MPTP triggers the presentation of proteins decorated with sLeX in mouse brain. MPTP triggers the expression of sLeX rate-limiting enzyme FUT 7 in striatum. sLeX is expressed in neurons, including dopaminergic neurons, and microglia. sLeX in the brain may have a role in neuronal signalling and immunomodulation.Keywords
Funding Information
- Fundação para a Ciência e a Tecnologia (PTDC/NEU-NMC/0248/2012, SFRH/BPD/72891/2010, UID/DTP/04138/2013, UIDP/04378/2020, UIDB/04378/2020)
- Universidade Nova de Lisboa
This publication has 50 references indexed in Scilit:
- S100B is increased in Parkinson’s disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-α pathwayBrain, 2012
- Transcriptional control of glyoxalase 1 by Nrf2 provides a stress-responsive defence against dicarbonyl glycationBiochemical Journal, 2012
- Sialyl Lewisx-dependent binding of human monocyte-derived dendritic cells to selectinsBiochemical and Biophysical Research Communications, 2011
- Region-Specific Protein Abundance Changes in the Brain of MPTP-Induced Parkinson’s Disease Mouse ModelJournal of Proteome Research, 2010
- Human fucosyltransferase IX: Specificity towards N-linked glycoproteins and relevance of the cytoplasmic domain in intra-Golgi localizationBiochimie, 2008
- Integrated mass spectrometric strategy for characterizing the glycans from glycosphingolipids and glycoproteins: direct identification of sialyl Lex in miceGlycobiology, 2007
- Selectins and glycosyltransferases in leukocyte rolling in vivoThe FEBS Journal, 2006
- Parkinson's DiseaseNeuron, 2003
- alpha1,3-Fucosyltransferase IX (Fut9) determines Lewis X expression in brainGlycobiology, 2003
- Differential expression of Lewisx and sialyl‐Lewisx antigens in fetal human neural cells in cultureJournal of Neuroscience Research, 1994